Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 14;22(1):701.
doi: 10.1186/s13063-021-05650-6.

YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial

Qing-Juan Wu  1 , Wen-Liang Lv  2 , Juan-Mei Li  1 , Ting-Ting Zhang  1 , Wen-Hui Zhou  1 , Qiang Zhang  1 , Jiu-Chong Wang  1 , Qing-Nan Wang  1 , Zi-Ang Yao  1   3 , Rui Qiang  1 , Si-Tong Chen  1   3 , Xin Zhao  1   3 , Shuang Liu  1 , Zheng-Min Cao  1   3 , Lei Xu  1   3 , Gao-Hui Li  1 , Jing Chen  1 , Li Wang  1   3
Affiliations

YinQiSanHuang Jiedu decoction for the treatment of hepatitis B-related compensated liver cirrhosis: study protocol for a multi-center randomized controlled trial

Qing-Juan Wu et al. Trials. .

Abstract

Introduction: Hepatitis B-related compensated liver cirrhosis is related to a higher risk of hepatocellular carcinoma, and antiviral therapy is the preferred method. As the pathological mechanisms of liver fibrosis are complex, drugs developed for a single target are difficult to be effective in clinical practice, so there are no chemical drugs or biological drugs with clear efficacy available for clinical application at present. Traditional Chinese medicine is a kind of medical science that has been gradually formed during thousands of years and continuously enriched by the people of all ethnic groups in China. Traditional Chinese medicine shows curative effects in the treatment of liver diseases, especially in the field of liver fibrosis prevention and treatment. This study aims to test the integrative medicine (Chinese medicine plus antiviral therapy) effective on lowing hepatocellular carcinoma risk among patients with hepatitis-related compensated liver cirrhosis.

Methods and analysis: This is a multi-center randomized controlled trial, and a total of 5 hospitals and 802 patients will be involved in. All the subjects are randomly allocated to the YinQiSanHuang Jiedu decoction (YQSHD) group (n = 401) or the placebo group (n = 401). The YQSHD group receives YQSHD granule with entecavir (ETV), and the placebo group receives YQSHD placebo with ETV. The treatment period will last for 52 weeks, and the follow-up period for 52 ± 2 weeks. The primary outcome measure is the annual incidence of HCC. Outcomes will be assessed at baseline and after treatment. The objective of this trial is "the integrative of YQSHD with ETV reduce the annual incidence of HCC to 1%."

Ethics and dissemination: The protocol has been approved by the Medical Ethics Committee of Guang'anmen Hospital, China (No.2019-006-KY), and the other centers in the trial will not begin recruiting until the local ethical approval has been obtained. Trial final results will be disseminated via publication.

Trial registration: Chinese Clinical Trial Registry ChiCTR1900021532 . Registered on February 26, 2019.

PubMed Disclaimer

Conflict of interest statement

All authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow diagram of the randomized, placebo-controlled, double-blinded trial of YQSHD for hepatitis B-related compensated liver cirrhosis
Fig. 2
Fig. 2
The schedule of enrollment, interventions, and assessments demonstrated in the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Trautwein C, Friedman SL, Schuppan D, Pinzani M. Hepatic fibrosis: concept to treatment. J Hepatol. 2015;62(1):15–24. doi: 10.1016/j.jhep.2015.02.039. - DOI - PubMed
    1. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol. 2008;48(2):335–352. doi: 10.1016/j.jhep.2007.11.011. - DOI - PubMed
    1. Kim SU, Chon YE, Seo YS, et al. A multi-center study of trends in hepatitis B virus-related hepatocellular carcinoma risk over time during long-term entecavir therapy. J Viral Hepat. 2020;27(12):1352–1358. doi: 10.1111/jvh.13384. - DOI - PubMed
    1. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52(3):886–893. doi: 10.1002/hep.23785. - DOI - PubMed
    1. Sun DJ, Zhu LJ, Yao DH, et al. Recent progress in potential anti-hepatitis B virus agents: structural and pharmacological perspectives. Eur J Med Chem. 2018;147:205–217. doi: 10.1016/j.ejmech.2018.02.001. - DOI - PubMed

Publication types

MeSH terms